Walvis

About The Fund

Walvis, also operating under the guise of Evonik Venture Capital, is a Corporate Venture Capital unit strategically engaged in cementing Evonik's reputation as a pre-eminent specialty chemicals company. With headquarters in Rellinghauser Strasse 111, Essen, Germany, they invest primarily in startups within attractive and rapidly growing markets. Walvis specializes in equity investments and operates as a Fund of Funds, boasting an impressive 100 million assets under management. Their focus is squarely set on companies at the seed, startup, and early-stage levels, with a minimum investment threshold of 5 million. They have a diversified portfolio with a keen interest in sectors such as Software, Information Technology, Telecommunications, Media Technology (TMT), Financial Services including FinTech, HealthTech, Fitness, Healthcare, Logistics, and Distribution. The fund's investment thesis hinges on fostering innovation in precision biosolutions, accelerating energy transition, and enabling a circular economy. They target solutions that support industries in transitioning towards more sustainable production models, embodying an ethos to build a better future in partnership with Nature. Walvis’s recent investments include ventures that develop biotechnological innovations for various industries, vegan cosmetical solutions, sustainable plastic additives, advancements in electromobility through battery technology, and post-surgery pain management implants. Additionally, they have expanded their venture capital efforts into Japan and are invested in sustainability-focused funds, further reinforcing their commitment to sustainability and innovation. As a brand of Evonik Industries, Walvis leverages its corporate backing to propel startups that align with their strategic growth areas and showcase potential for substantial impact within Evonik's broader mission.